GlassScriptPhysician profile
Lindsey Holland
NPI 1245840032
$2,999.32
in general payments reported to CMS, 2019-2025
28 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $646 · 2023: $1,017 · 2024: $631 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.39 |
| Education | $259.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $422.12 | 2021-2025 | Opdivo, Augtyro |
| Janssen Biotech, INC. | $392.91 | 2022-2025 | Rybrevant, Erleada, Akeega |
| Incyte Corporation | $296.85 | 2022-2024 | Jakafi, Monjuvi |
| Genentech USA, INC. | $204.60 | 2022-2024 | Ocrevus, Alecensa, Lunsumio |
| Amgen INC. | $189.38 | 2021-2022 | |
| Seagen INC. | $170.31 | 2021-2023 | Padcev, Adcetris |
| Astrazeneca Pharmaceuticals LP | $149.50 | 2021-2024 | Wainua |
| Mirati Therapeutics, INC. | $143.93 | 2023 | Krazati |
| Genzyme Corporation | $123.09 | 2021 | |
| Btg International INC. | $112.57 | 2021 | |
| Daiichi Sankyo INC. | $103.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $87.46 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $70.39 | 2023-2024 | Keytruda, Lynparza |
| Coherus Oncology, INC. | $60.25 | 2023 | |
| Abbvie INC. | $58.23 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.36 | 2023-2024 | Fruzaqla, Entyvio |
| Novocure INC. | $51.82 | 2025 | Optune Lua (Novottf-200t) |
| Astellas Pharma US INC | $42.25 | 2024 | Xtandi |
| Lilly USA, LLC | $37.81 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $36.79 | 2023 | Xpovio |
| Beigene USA, INC. | $34.70 | 2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $29.77 | 2023 | Tazverik |
| Cti Biopharma Corp. | $24.96 | 2023 | Vonjo |
| Gilead Sciences, INC. | $24.15 | 2023 | |
| Exelixis INC. | $22.45 | 2023 | Cabometyx |
| Celgene Corporation | $22.43 | 2023 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $17.94 | 2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $16.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.